Ozempic
Ozempic is FDA-approved for type 2 diabetes and prescribed off-label for weight loss. Compare cost, coverage, and how it differs from Wegovy.
- Manufacturer
- Novo Nordisk
- Drug class
- GLP-1 receptor agonist
- Dose range
- 0.25 mg → 2.0 mg weekly
- Average monthly cost
- $968 without insurance · $25 with most diabetes plans
- Insurance covered
- Often, with prior authorization
Overview
Ozempic is the same active ingredient as Wegovy — semaglutide — but FDA-labeled for type 2 diabetes rather than weight loss. It is dosed up to 2.0 mg weekly (versus Wegovy's 2.4 mg) and is significantly cheaper at cash price. Many patients without diabetes get it prescribed off-label for weight management.
How it works
Same mechanism as Wegovy: semaglutide slows gastric emptying, reduces appetite, and improves insulin response. Weight loss is a documented secondary effect.
Side effects
- Nausea and decreased appetite
- GI side effects: diarrhea, constipation, vomiting
- Possible injection-site reactions
- Rare: pancreatitis, gallbladder issues
Who should consider Ozempic
Adults with type 2 diabetes, or adults with obesity whose clinician prescribes it off-label. Insurance coverage for weight loss is rare without a diabetes diagnosis.
Telehealth programs that prescribe Ozempic
Editorial only — not medical advice. Drug pricing and availability change frequently; verify with the prescribing program before relying on any figure on this page.